Cargando…

Reply: Unblinding in the lecanemab trial in Alzheimer’s disease

Detalles Bibliográficos
Autores principales:	Hardy, John, Mummery, Catherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629754/ https://www.ncbi.nlm.nih.gov/pubmed/37609937 http://dx.doi.org/10.1093/brain/awad201

Ejemplares similares

Reply: Lecanemab: turning point, or status quo? An ethics perspective
por: Hardy, John, et al.
Publicado: (2023)

Lecanemab: A hope in the management of Alzheimer’s disease
por: Thakkar, Nandita, et al.
Publicado: (2023)

The unblinding of statisticians in clinical trials: commentary on Iflaifel et al., Trials 2023
por: Parker, Richard A.
Publicado: (2023)

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint
por: Jönsson, Linus, et al.
Publicado: (2023)

Natural unblinding of BCG vaccination trials
por: Szigeti, Reka, et al.
Publicado: (2021)

Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials
por: Qiao, Yue, et al.
Publicado: (2023)

Estimated Societal Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

The Potential Economic Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation
por: Igarashi, Ataru, et al.
Publicado: (2023)

Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

A Path to Improved Alzheimer’s Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer’s Disease from the CLARITY AD Trial
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

Reply: Implications of presymptomatic change in thalamus and caudate in Alzheimer’s disease
por: Ryan, Natalie S., et al.
Publicado: (2013)

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease
por: Honig, Lawrence S., et al.
Publicado: (2023)

Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial
por: Berry, Donald A., et al.
Publicado: (2023)

Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease
por: Dhadda, Shobha, et al.
Publicado: (2022)

Anti-amyloid therapies work for Alzheimer’s disease
por: Hardy, John
Publicado: (2023)

Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer’s disease: A systematic review
por: Chowdhury, Selia, et al.
Publicado: (2023)

Effect of Lecanemab and Donanemab in Early Alzheimer’s Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective
por: Volloch, Vladimir, et al.
Publicado: (2023)

Reply to the letter titled, “Dementia with Lewy Bodies and Alzheimer's Disease Sometimes Coexist”
por: Tsujimoto, Masashi
Publicado: (2022)

Reply: Parkinson’s disease in GTP cyclohydrolase 1 mutation carriers
por: Mencacci, Niccolo E., et al.
Publicado: (2015)

Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab
por: Shi, Mingchao, et al.
Publicado: (2022)

Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease
por: Hayato, Seiichi, et al.
Publicado: (2022)

Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease
por: Söderberg, Linda, et al.
Publicado: (2022)

An anti-amyloid therapy works for Alzheimer’s disease: why has it taken so long and what is next?
por: Hardy, John, et al.
Publicado: (2023)

Blinded and unblinded sample size reestimation in crossover trials balanced for period
por: Grayling, Michael J., et al.
Publicado: (2018)

Lecanemab reduces brain amyloid-β and delays cognitive worsening
por: Knopman, David S.
Publicado: (2023)

Home phototherapy for hyperbilirubinemia in term neonates—an unblinded multicentre randomized controlled trial
por: Pettersson, M., et al.
Publicado: (2021)

Reply
por: Vintzileos, William S., et al.
Publicado: (2020)

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
por: Swanson, Chad J., et al.
Publicado: (2021)

Reply
por: Alvarez, Ronald D., et al.
Publicado: (2021)

Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer’s Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab
por: Melo, V. S. D., et al.
Publicado: (2023)

Reply: antioxidant trials—the need to test for stress
por: Kamath, Mohan S, et al.
Publicado: (2021)

In Reply
por: Brennen, W. Nathaniel, et al.
Publicado: (2019)

Authors’ reply
por: Krishna, Bhuvana, et al.
Publicado: (2014)

Authors’ reply
por: Moschos, John M., et al.
Publicado: (2015)

Authors' reply
por: Murthy, GVS, et al.
Publicado: (2009)

Authors’ reply
por: George, Shyjumon, et al.
Publicado: (2012)

Blinded and unblinded sample size reestimation procedures for stepped‐wedge cluster randomized trials
por: Grayling, Michael J., et al.
Publicado: (2018)

Ethical Considerations for Unblinding and Vaccinating COVID-19 Vaccine Trial Placebo Group Participants
por: Stoehr, Jenna Rose, et al.
Publicado: (2021)

Author's reply
por: Gogate, Parikshit, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_t2lo1hdsl1nvm1stctggreuoh0